Implant Sciences to raise $8.5 million in IPO (initial public offering):
This article was originally published in Clinica
Implant Sciences, which is developing radioactive prostate seeds and coronary stents, plans to raise up to $8.5 million in an initial public offering on the Nasdaq SmallCap market and the Boston stock exchange. The Wakefield, Massachusetts-based company is to offer one million units - each one comprising one share of common stock and one redeemable common stock purchase warrant - for between $7 and $8.50 each. The company is also developing engineered surfaces for interventional cardiology devices (radiopaque stents, guidewires and catheters).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.